Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

8.910 +0.060 (+0.68%)
Streaming Delayed Price Updated: 9:45 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 194,163
Open 8.930
Bid (Size) 8.910 (200)
Ask (Size) 8.920 (100)
Prev. Close 8.850
Today's Range 8.870 - 9.020
52wk Range 5.250 - 10.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xeris (XERS) Q2 2026 Earnings Call Transcript ↗
Recorlev revenue surged 81% year-over-year, driving tightened full-year guidance to $385M–$390M. 
Via The Motley Fool
Topics Earnings Intellectual Property Retirement
News headline image
Xeris Biopharma Q2 Earnings Call Highlights ↗
Xeris Biopharma (NASDAQ:XERS) reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of... 
Via MarketBeat
Topics Earnings Retirement

Performance

YTD
+21.2%
+21.2%
1 Month
+3.6%
+3.6%
3 Month
+50.5%
+50.5%
6 Month
+28.9%
+28.9%
1 Year
+21.1%
+21.1%

More News

Read More
News headline image
Xeris Biopharma Reports Second Quarter 2026 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge ↗
Via Chartmill
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook ↗
Via Chartmill
News headline image
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Updates to Its Board of Directors
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Private Exchange of Convertible Notes
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Xeris (XERS) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Xeris Biopharma Reports First Quarter 2026 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
Via The Motley Fool
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗
Via The Motley Fool

Frequently Asked Questions

Is Xeris Biopharma Holdings, Inc. - Common Stock publicly traded?
Yes, Xeris Biopharma Holdings, Inc. - Common Stock is publicly traded.
What exchange does Xeris Biopharma Holdings, Inc. - Common Stock trade on?
Xeris Biopharma Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock?
The ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock is XERS on the Nasdaq Stock Market
What is the current price of Xeris Biopharma Holdings, Inc. - Common Stock?
The current price of Xeris Biopharma Holdings, Inc. - Common Stock is 8.910
When was Xeris Biopharma Holdings, Inc. - Common Stock last traded?
The last trade of Xeris Biopharma Holdings, Inc. - Common Stock was at 08/19/26 09:45 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.